Schrödinger, Inc. 8-K

Summary

Cash proceeds from Eli Lilly’s completed acquisition of Ajax Therapeutics, which Schrödinger co-founded. Schrödinger received an upfront payment and may receive additional cash if Ajax achieves specified clinical and regulatory milestones.

Key Figures

• Cash payment received: ≈$57M.
• Additional cash payments are contingent on Ajax achieving specified clinical and regulatory milestones.

Investor Takeaways

• Future Ajax clinical and regulatory milestone achievements determine whether Schrödinger receives additional payments; the filing gives no amounts or timing.